Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

642
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
642
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.

Gut·2025
Same author

Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.

BMC cancer·2020
Same author

Intestinal perforation during chemotherapeutic treatment of intra-abdominal desmoid tumor in patients with Gardner's syndrome: report of two cases.

World journal of surgical oncology·2016
Same author

Rapid diagnosis of aneuploidy using segmental duplication quantitative fluorescent PCR.

PloS one·2014
Same author

[Relationship between activated STAT3 protein and epithelial-mesenchymal transition in papillary thyroid carcinoma].

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery·2014

Related Experiment Video

Updated: Aug 26, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

Immunotherapy for liposarcoma: emerging opportunities and challenges.

Zhengqing Song1, Lili Lu2, Zixu Gao3

  • 1Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Future Oncology (London, England)
|October 10, 2022
PubMed
Summary

Liposarcoma (LPS) immunotherapy shows promise for this rare cancer. Research explores its tumor microenvironment and novel treatment strategies to improve durable responses.

Keywords:
adoptive cell therapycancer vaccinesimmune checkpoint inhibitorsimmunotherapyliposarcomaoncolytic virusessoft tissue sarcomatumor-infiltrating lymphocytes

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

Related Experiment Videos

Last Updated: Aug 26, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Liposarcoma (LPS) is a rare soft tissue sarcoma originating from fat cells, comprising 20% of all soft tissue sarcomas.
  • Current treatments like surgery and chemotherapy face challenges due to large tumor burden and high recurrence rates, particularly in advanced disease.
  • Advances in immunotherapy for other cancers have spurred interest in its application for LPS.

Purpose of the Study:

  • To review the current understanding of the liposarcoma tumor microenvironment.
  • To summarize the status of various immunotherapeutic strategies being explored for LPS treatment.
  • To identify future directions for enhancing immunotherapy efficacy and durability in liposarcoma.

Main Methods:

  • Literature review of existing research on liposarcoma and immunotherapy.
  • Analysis of the tumor microenvironment's role in LPS development and progression.
  • Evaluation of current immunotherapeutic approaches including immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, oncolytic viruses, and combination therapies.

Main Results:

  • The tumor microenvironment of LPS presents unique characteristics influencing treatment response.
  • Several immunotherapeutic modalities are under investigation for LPS, showing potential but requiring further validation.
  • Combination therapies and novel strategies are being explored to overcome treatment resistance and improve outcomes.

Conclusions:

  • Immunotherapy holds significant potential for treating liposarcoma, a challenging malignancy.
  • Further research into the LPS tumor microenvironment and advanced immunotherapeutic strategies is crucial.
  • Optimizing and combining different immunotherapies may lead to more effective and durable treatments for liposarcoma patients.